How should I use Exkivity(Mobocertinib)?

EXKIVITY is administered orally once daily, with specific dose adjustments recommended for adverse reactions, concomitant use of moderate CYP3A inhibitors, and in patients with severe renal impairment to optimize safety and tolerability.

EXKIVITY Administration and Dose Management 

The standard recommended dosage of EXKIVITY is 160 mg taken orally once daily, consistently at the same time each day, with or without food. Capsules should be swallowed whole and not opened, chewed, or dissolved. If a dose is missed by more than six hours, it should be skipped, and the next dose taken at the regularly scheduled time the following day. 

If vomiting occurs after a dose, an additional dose should not be taken; the next dose should be administered as scheduled. Dose reduction levels for adverse reactions are established at 120 mg and 80 mg once daily. For patients concurrently using moderate CYP3A inhibitors or those with severe renal impairment (eGFR <30 mL/min/1.73 m²), the EXKIVITY dose should be reduced by approximately 50% (e.g., 160 mg to 80 mg), with increased QTc monitoring.